In a phase 2b trial, around half of patients taking the novel calcineurin inhibitor at a dose of 23.7 mg twice daily achieved complete remission at 48 weeks.

Lupus nephritis patients can be good candidates if their disease is quiescent for at least one year prior to surgery.